A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 Viruses

Journal of Virology

Volumn 86, Issue 12, 2012, Pages 6970-6978

  Zhou, Fan ^a   Wang, Guiqin ^a   Buchy, Philippe ^b   Cai, Zhipeng ^c   Chen, Honglin ^d   Chen, Zhiwei ^e   Cheng, Genhong ^f   Wan, Xiu Feng ^c   Deubel, Vincent ^b   Zhou, Paul ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^c MISSISSIPPI STATE UNIVERSITY   (United States)

^d THE UNIVERSITY OF HONG KONG   (Hong Kong)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; PLASMID DNA;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CD8+ T LYMPHOCYTE; CLADISTICS; CODON; CONTROLLED STUDY; CROSS REACTION; DRUG POTENCY; DRUG SCREENING; FEMALE; IC 50; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PSEUDOTYPING; SEROLOGY; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AVES; MUS; MUSTELA; ORTHOMYXOVIRIDAE;

EID: 84863994618     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06930-11     Document Type: Article

References (47)

1. Barr IG, et al. 2010. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2), and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 northern hemisphere season. Vaccine 28:1156- 1167.
2. Bommakanti G, et al. 2010. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc. Natl. Acad. Sci. U. S. A. 107:13701-13706.
3. Bright RA, et al. 2008. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 3:e1501. doi:10.1371/journal.pone.0001501.
4. Buchy P, et al. 2007. Influenza A/H5N1 virus infection in humans in Cambodia. J. Clin. Virol. 39:164 -168.
5. Cai Z, Zhang T, Wan X-F. 2010. A computational framework for influenza antigenic cartography. PLoS Comput. Biol. 6:e1000949. doi:10.1371/ journal.pcbi.1000949.
6. Carrat F, Flahault A. 2007. Influenza vaccine: the challenge of antigenic drift. Vaccine 25:6852- 6862.
7. Chen MW, et al. 2008. A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc. Natl. Acad. Sci. U. S. A. 105:13538 -13543.
8. Corti D, et al. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120:1663-1673.
9. Corti D, et al. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333:850-856.
10. Crevar CJ, Ross TM. 2008. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol. J. 5:131-139.
11. Deng Y, Yewdell JW, Eisenlohr LC, Bennink JR. 1997. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J. Immunol. 158:1507-1515.
12. Ding H, et al. 2011. Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus. PLoS One 6:e16563. doi:10.1371/ journal.pone.0016563.
13. Ducatez MF, et al. 2011. Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development. Proc. Natl. Acad. Sci. U. S. A. 108:349 -354.
14. Ehrlich HJ, et al. 2009. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J. Infect. Dis. 200:1113- 1118.
15. Ekiert DC, et al. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324:246 -251.
16. Ekiert DC, et al. 2011. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333:843- 850.
17. 2011 FAO. FAO ECTAD HPAI situation update no. 500. Food and Agriculture Association, New York, NY.
18. Forrest HL, et al. 2009. Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. Vaccine 27:4187- 4195.
19. Gerhard W, et al. 1990. Identification of eight determinants in the hemagglutinin molecule of influenza virus A/PR/8/34 (H1N1) which are recognized by class II-restricted T cells from BALB/c mice. J. Virol. 65:364- 372.
20. Giles BM, Ross TM. 2011. A computationally optimized broadly reactiveantigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 29:3043-3054.
21. Kong WP, et al. 2003. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J. Virol. 77:12764 -12772.
22. Li Y, et al. 2010. Continued evolution of H5N1 influenza viruses in wild birds, domestic poultry, and humans in China from 2004 to 2009. J. Virol. 84:8389-8397.
23. Nguyen T, et al. 2009. Characterization of a highly pathogenic avian influenza H5N1 virus sublineage in poultry seized at ports of entry into Vietnam. Virology 387:250 -256.
24. Okuno Y, Isegawa Y, Sasao F, Ueda S. 1993. A common neutralizing epitope conserved between the hemagglutinins of influenza A Virus H1 and H2 strains. J. Virol. 67:2552-2558.
25. + T Cells. J. Immunol. 171:1999 -2005.
26. Prabakaran M, et al. 2010. Neutralizing epitopes of influenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages. J. Virol. 84:11822-11830.
27. Rao S, et al. 2008. Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. PLoS One 3:e2432. doi:10.1371/journal.pone.0002432.
28. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Epidemiol. 27:493- 497.
29. Smith GJ, et al. 2006. Emergence and predominance of an H5N1 influenza variant in China. Proc. Natl. Acad. Sci. U. S. A. 103:16936 -16941.
30. Steel J, et al. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 1:e00018-10. doi:10.1128/mBio.00018-10.
31. Sui J, et al. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16:265-273.
32. Tao P, et al. 2009. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice. Viral Immunol. 22:273-281.
33. + memory B cells. PLoS One 3:e3942. doi:10.1371/journal.pone. 0003942.
34. Tsai C, et al. 2009. Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. Vaccine 27: 6777-6790.
35. Wan XF, et al. 2011. Indications that live poultry markets are a major source of human H5N1 influenza virus infection in China. J. Virol. 85: 13432-13438.
36. Wang TT, et al. 2010. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. U. S. A. 107:18979 -18984.
37. Wei CJ, et al. 2010. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329:1060 -1064.
38. 2012 WHO. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines. World Health Organization, Geneva, Switzerland.
39. 2011 WHO. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. World Health Organization, Geneva, Switzerland.
40. 2012 WHO. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2012. World Health Organization, Geneva, Switzerland.
41. 2011 WHO. H5N1 avian influenza: timeline of major events. World Health Organization, Geneva, Switzerland.
42. 2008 WHO. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358:261-273.
43. Wrammert J, et al. 2008. Rapid cloning of high affinity human monoclonal antibodies against influenza virus. Nature 453:667- 671.
44. Wu WL, et al. 2008. Antigenic profile of avian H5N1 viruses in Asia from 2002 to 2007. J. Virol. 82:1798 -1807.
45. Yang ZY, et al. 2004. pH-dependent entry of Severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J. Virol. 78:5642- 5650.
46. Yang ZY, et al. 2007. Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science 317:825- 828.
47. Zhou B, Zhong N, Guan Y. 2007. Treatment with convalescent plasma for influenza A (H5N1) infection. N. Engl. J. Med. 357:1450 -1451.